By Fineline Cube 
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical trial for its fixed-dose combination (FDC) of prusogliptin and metformin. The study will evaluate the safety and efficacy of this novel combination in adults with type 2 diabetes mellitus (T2DM) who have an inadequate response to metformin alone or are currently undergoing combination therapy with prusogliptin and metformin.
Innovative Combination Therapy
This first-in-class FDC combines prusogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances glucose-dependent insulin secretion, with metformin, the first-line biguanide agent that reduces hepatic gluconeogenesis. The combination aims to provide improved glycemic control for patients with T2DM.-Fineline Info & Tech